Research programme: infectious diseases therapeutics - Achillion/Millenia Hope Biopharma

Drug Profile

Research programme: infectious diseases therapeutics - Achillion/Millenia Hope Biopharma

Latest Information Update: 01 Apr 2008

Price : $50

At a glance

  • Originator Achillion Pharmaceuticals; Millenia Hope Biopharma
  • Class Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Bacterial infections; Viral infections

Most Recent Events

  • 21 Feb 2006 Avance Pharma has been acquired and merged into Millenia Hope Biopharma
  • 06 Apr 2004 Phytobiotech is now called Avance Pharma
  • 23 Apr 2003 Preclinical trials in Viral infections in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top